ORIC — ORIC Pharmaceuticals, Inc. stock price, charts and financials

Latest market price

10.60

-0.47-4.25%

Overview Short InterestFilings

ORICQT62ORIC Pharmaceuticals, Inc.·NASDAQ

Overview Short InterestFilings

10.60-4.25%

News

Down 4.2% — ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates (globenewswire.com).

Medium confidence

Loading chart...

Signal & projected range

QT Score downgradeHistorical pattern — not a prediction

Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

IOVA+6.14%$4.32 FTRE-1.20%$18.94 SLS+12.09%$11.22 URGN+0.92%$38.59 MESO+2.12%$14.47 TSHA-1.37%$5.78 TYRA+0.50%$32.04 AUPH-2.08%$14.57

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	18.44%	Shs Outstand	103.52M	Perf Week	-8.51%

Market Cap	1.15B	Forward P/E	-	EPS next Y	-1.60	Insider Trans	-0.34%	Shs Float	48.71M	Perf Month	1.65%

Enterprise Value	1.09B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	45.28%	Perf Quarter	12.04%

Income	-132.70M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	13.63	Perf Half Y	2.88%

Sales	0.00	P/B	2.81	EPS next Y	-9.27%	ROA	-30.96%	Short Interest	22.05M	Perf YTD	35.33%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-35.33%	52W High	14.30 -25.85%	Perf Year	3.36%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-35.50%	52W Low	6.92 53.11%	Perf 3Y	26.95%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	6.48% 6.91%	Perf 5Y	-35.83%

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	21.31%	Oper. Margin	0.00%	ATR (14)	0.75	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	16.33	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	53.72	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	16.33	EPS Q/Q	19.05%	SMA20	0.18%	Beta	0.96	Target Price	18.33

Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	-	SMA50	14.61%	Rel Volume	0.74	Prev Close	11.07

Employees	104	LT Debt/Eq	0.02	Earnings	Aug 11	SMA200	4.64%	Avg Volume	1.67M	Price	10.60

IPO Date	Apr 24, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-6.00% -	Net Debt/EBITDA	0.40	Volume	1,238,821	Change	-4.25%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-15-26	Reiterated	Goldman Sachs		$15
Feb-24-26	Reiterated	Oppenheimer	Outperform	$12 → $15
Feb-24-26	Reiterated	HC Wainwright & Co.	Buy	$23 → $25
Jan-07-26	Initiated	Piper Sandler	Overweight	$22
Dec-08-25	Reiterated	Wells Fargo	Overweight	$25
Nov-14-25	Reiterated	HC Wainwright & Co.	Buy	$21 → $23
Sep-04-25	Reiterated	Guggenheim	Buy	$18
May-06-25	Reiterated	Oppenheimer	Outperform	$17 → $12
Sep-05-24	Initiated	Stifel	Buy	$20
Mar-21-24	Reiterated	HC Wainwright & Co.	Buy	$21

Latest News

Today

Today04:05PM

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updatesglobenewswire.com

Jul-24-26

Jul-24-2601:05PM

12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga

Jul-21-26

Jul-21-2610:30AM

ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen The Bull Caseseekingalpha.com

Jul-20-26

Jul-20-2608:30AM

ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026globenewswire.com

Jul-14-26

Jul-14-2604:07PM

ORIC®Pharmaceuticals Initiates Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat In Combination With NUBEQABenzinga

04:05PM

ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayerglobenewswire.com

Jul-02-26

Jul-02-2604:30PM

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Jun-15-26

Jun-15-2608:01AM

Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market SessionBenzinga

Company

ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018	FY 2017 12/31/2017
Total Revenue	0	0	0	0	0	0	0	0	0
Cost of Goods Sold Incl. D&A	1	1	1	0	0	0	1	1	1
Gross Profit	-1	-1	-1	0	0	0	-1	-1	-1
Selling, General and Administrative Excl. Other	33	29	26	25	22	13	5	3	3
Research and Development	110	114	85	62	57	61	23	19	19
Other Operating Expense	-1	-1	-1	5	0	0	0	0	0
Operating Income	-143	-143	-111	-92	-79	-74	-29	-22	-23
Interest Expense	0	0	0	3	0	0	0	0	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	14	15	10	5	0	0	2	1	1
Net Income Before Taxes	-129	-128	-101	-89	-79	-74	-27	-21	-22
Income Taxes	0	0	0	0	0	0	0	0	0
Consolidated Net Income	-129	-128	-101	-89	-79	-74	-27	-21	-22
Net Income From Continuing Operations	-129	-128	-101	-89	-79	-74	-27	-21	-22
Net Income	-129	-128	-101	-89	-79	-74	-27	-21	-22
EPS (Recurring)	-1.47	-1.83	-1.96	-2.25	-2.07	-3.36	-1.40	-12.32	-15.62
EPS (Basic, Before Extraordinaries)	-1.47	-1.83	-1.96	-2.25	-2.07	-3.36	-1.40	-12.32	-15.62
EPS (Diluted)	-1.47	-1.83	-1.96	-2.25	-2.07	-3.36	-1.40	-12.32	-15.62
EBITDA	-128	-127	-100	-86	-78	-48	-26	-20	-21
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—	—
Shares Outstanding	88	70	51	40	38	22	2	2	1
Market Capitalization	720	565	469	236	559	745	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heyman Richard A.	Director	Jul 24 '26	Sale	12.02	13,100	157,462	38,300	Jul 28
Heyman Richard A.	Director	Jul 24 '26	Option Exercise	1.60	3,500	5,600	45,300	Jul 28
Heyman Richard A.	Director	Jul 06 '26	Sale	12.00	300	3,600	212,772	Jul 08
Piscitelli Dominic	Chief Financial Officer	Feb 24 '26	Option Exercise	4.36	52,000	226,720	120,148	Feb 26
Piscitelli Dominic	Chief Financial Officer	Feb 24 '26	Sale	13.51	52,000	702,686	68,148	Feb 26
Heyman Richard A.	Director	Jan 16 '26	Sale	12.00	6,700	80,431	41,800	Jan 20
Multani Pratik S	Chief Medical Officer	Dec 16 '25	Sale	9.06	10,720	97,129	68,149	Dec 17
Piscitelli Dominic	Chief Financial Officer	Dec 16 '25	Sale	9.06	10,720	97,127	68,148	Dec 17
Chacko Jacob	PRESIDENT AND CEO	Dec 16 '25	Sale	9.06	33,374	302,368	581,711	Dec 17
Multani Pratik S	Chief Medical Officer	Dec 15 '25	Option Exercise	0.00	58,666	0	78,869	Dec 17
Piscitelli Dominic	Chief Financial Officer	Dec 15 '25	Option Exercise	0.00	58,666	0	78,868	Dec 17
Chacko Jacob	PRESIDENT AND CEO	Dec 15 '25	Option Exercise	0.00	167,332	0	615,085	Dec 17
Kunkel Lori Anne	Director	Dec 08 '25	Option Exercise	7.90	10,000	79,000	84,200	Dec 09
Kunkel Lori Anne	Director	Dec 04 '25	Option Exercise	3.75	5,534	20,753	74,200	Dec 05
Piscitelli Dominic	Chief Financial Officer	Oct 06 '25	Sale	14.52	11,000	159,719	48,317	Oct 08

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.